1	Genetic estimates of correlation and causality between blood-based
2	biomarkers and psychiatric disorders
3	
4	William R. Reay ^{1,2} , Dylan J. Kiltschewskij ^{1,2} , Michael P. Geaghan ^{1,2} , Joshua R. Atkins ¹ ,
5	Vaughan J. Carr ^{3,4,5} , Melissa J. Green ^{3,4} , Murray J. Cairns ^{1,2} *
6	
7	¹ School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan,
8	NSW, Australia
9	² Centre for Brain and Mental Health Research, Hunter Medical Research Institute,
10	Newcastle, NSW, Australia
11	³ School of Psychiatry, University of New South Wales, Randwick, NSW, Australia
12	⁴ Neuroscience Research Australia, Sydney, NSW, Australia
13	⁵ Department of Psychiatry, Monash University, Melbourne, VIC, Australia
14	
15	To whom correspondence should be addressed: Professor Murray Cairns
16	(<u>Murray.Cairns@newcastle.edu.au</u>)
17	
18	Running title: Biochemical traits and psychiatric disorders
19	
20	Keywords: genome-wide association study, genetic correlation, causal inference,
21	biochemical traits, pleiotropy, psychiatric illness
22	
23	
24	
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ABSTRACT

There is a long-standing interest in exploring the relationship between blood-based biomarkers 26 of biological exposures and psychiatric disorders, despite their causal role being difficult to 27 resolve in observational studies. In this study, we leverage genome-wide association study data 28 for a large panel of heritable biochemical traits measured from serum to refine our 29 30 understanding of causal effect in biochemical-psychiatric trait parings. In accordance with 31 expectation we observed widespread evidence of positive and negative genetic correlation 32 between psychiatric disorders and biochemical traits. We then implemented causal inference 33 to distinguish causation from correlation and found strong evidence that C-reactive protein (CRP) exerts a causal effect on psychiatric disorders, along with other putatively causal 34 relationships involving urate and glucose. Strikingly, these analyses suggested CRP has a 35 36 protective effect on three disorders including anorexia nervosa, obsessive-compulsive disorder, 37 and schizophrenia, whilst being a risk factor for major depressive disorder. Multivariable 38 models that conditioned CRP effects on interleukin-6 signalling and body mass index suggested that CRP-schizophrenia relationship was not likely mediated by those factors. 39 40 Collectively, these data suggest that there are shared pathways that influence both biochemical 41 traits and psychiatric illness, including factors such as CRP that are likely to constitute a causal 42 effect and could be targets for therapeutic intervention and precision medicine.

- 43
- 44
- 45 46
- 47
- 48
- 49

50 MAIN TEXT

51 INTRODUCTION

52 Psychiatric disorders arise from a complex interplay between genetic and environmental risk factors. Indeed, twin-based and genome-wide association (GWAS) studies' heritability 53 estimates have demonstrated the importance of genetic risk to the spectrum of psychiatric 54 illness (1–3). In particular, GWAS have been successful in identifying regions of the genome 55 56 associated with psychiatric disorders, as well as revealing both overlapping and distinct features amongst the genetic architecture of these traits (2-6). For example, our group 57 58 previously demonstrated that several genes associated with schizophrenia were shared with other psychiatric disorders, along with genes that appeared more specifically linked to 59 schizophrenia (4). The challenge for psychiatric genetics from here onwards is to integrate and 60 61 expand these data such that the biological insights gained may be directly relevant for 62 psychiatric practice.

63

64 GWAS has proven valuable beyond just gene discovery in psychiatry, in that it allows the study of relationships between sets of traits in terms of genetic correlation (7), as well as GWAS 65 informed methods for causal inference (8,9). An area of continued interest is the interplay 66 67 between circulating biochemical factors and the pathophysiology of psychiatric disorders (10-13). These studies have endeavoured to find biochemical traits readily detectable in blood, that, 68 in theory, could be diagnostic or prognostic biomarkers for a given psychiatric disorder. Many 69 70 of these hypotheses stem from the idea that peripheral biochemical traits may exert an effect 71 on the brain, directly or indirectly through their effect on other mediators, and that the 72 manifestation of mental illness is in part attributed to these factors which primarily act in the periphery (11,12,14–16). Identifying these biochemical-psychiatric relationships would be 73 clinically valuable as many of these traits can be modulated by existing drugs and/or lifestyle 74

interventions. However, progress in this field has been hampered by small sample size studies, along with the fact that the majority of these studies are observational in nature, and thus, likely subject to at least some confounding. Genetics offers an attractive prospect for studying biochemical traits in psychiatry as many such measures are heavily influenced by genetic factors, with germline genetic variants fixed at birth and immune to reverse causation in most instances. In this study, we attempt to harmonise inter-study variability by using a panel of large sample size (N > 300,000) biochemical GWAS from a single cohort (UK biobank) to investigate genetic overlap with different psychiatric disorders, along with putative causal effects. We found that the majority of biochemical traits tested were genetically correlated with at least one psychiatric trait, with evidence of convergent and divergent correlation profiles amongst the different disorders. Interestingly, we also demonstrated evidence that there may be a causal relationship on psychiatric phenotypes through circulating C-reactive protein (CRP), glucose, and urate – which may have direct implications for clinical practice.

100 METHODS AND MATERIALS

101 Psychiatric genome-wide association studies

102 GWAS summary statistics for nine European ancestry cohorts for the following disorders were obtained from the psychiatric genomics consortium (PGC): attention/deficit hyperactivity 103 104 disorder (ADHD) (17), anorexia nervosa (AN) (18), autism spectrum disorder (ASD) (19), bipolar disorder (BIP) (20), major depressive disorder (MDD) (21), obsessive compulsive 105 106 disorder (OCD), post-traumatic stress disorder (PTSD) (22), schizophrenia (SZ) (23), and 107 Tourette's syndrome (TS) (24). Given that cognitive symptoms are pervasively associated with 108 psychiatric illness, we also included a GWAS of general cognitive ability (25). Further information regarding these studies is provided in the supplementary text. 109

110

111 Blood-based biomarker genome-wide association studies

We obtained GWAS summary statistics for a series of blood-based biochemical traits from the 112 large UK biobank (UKBB) sample performed by the Neale group (http://www.nealelab.is/uk-113 biobank). The key advantage of these data is its large sample size (N > 300,000) and that the 114 115 biochemical traits analysed were obtained from a single large cohort. Specifically, we utilised a panel of 50 biochemical GWAS which had high or medium confidence estimates of SNP 116 heritability that were significantly different from zero as outlined in supplementary table 1 and 117 supplementary text. These traits included lipids, micronutrients, hormones, metabolites, and 118 119 enzymes.

120

121 Genetic correlation

Genetic correlation between each psychiatric and biochemical trait was estimated using linkage disequilibrium score regression (LDSR) (7), with summary statistic cleaned ('munged') to contain around one million HapMap 3 SNPs outside the major histocompatibility complex

(MHC) with minor allele frequency > 0.05 for consistency (https://github.com/bulik/ldsc). 125 Briefly, LDSR estimates genetic covariance by regressing SNP-wise χ^2 , the product of the 126 marginal SNP effects from both traits (Z_1Z_2) , on its LD score, which is an estimate of total LD 127 existing with that SNP. Trait hertiabilities are utilised to normalise the genetic covariance to 128 129 obtain genetic correlation (r_a) . A key advantage of LDSR is that sample overlap only affects the LDSR intercept and not the slope, meaning we can accurately estimate r_g between UKBB 130 biochemical GWAS and psychiatric GWAS with UKBB samples included. We used the 131 132 Bonferroni method to correct for the fifty traits tested. One biochemical trait was excluded 133 from further analysis, Apolipoprotein B, as it exhibited negative heritability within the block jackknifing procedure to estimate the r_q standard error in some instances. The resulting 49 x 134 10 matrix of LDSR r_g , divided by its standard error to obtain Z, was subjected to a latent 135 clustering method, finite Gaussian mixture modelling (GMM), with the mclust R package 136 137 version 5.4.6 (26). We selected the most parsimonious clustering configuration based on parametrisation of the covariance matrix utilising the largest Bayesian Information Criterion 138 139 (BIC) value.

140

141 Biochemical polygenic scoring in a severe cognitive deficit subtype of schizophrenia

We sought to further investigate biochemical traits displaying psychiatric genetic correlation 142 143 and examine their relevance to the clinical dimensions of psychiatric disorders. Specifically, we considered the heterogeneity of cognitive impairment observed in schizophrenia, wherein 144 deficits often manifest before the first psychotic episode and are highly variable in their 145 presentation throughout clinical course (27,28). We considered biochemical traits that were 146 147 genetically correlated with either schizophrenia or cognition after the application of multiple 148 testing correction and interrogated their relationship with severe cognitive deficit in a cohort of schizophrenia cases from the Australian Schizophrenia Research Bank (ASRB) cohort. The 149

150 use of these data was approved by the University of Newcastle Human Research Ethics Committee (HREC) and the ASRB (28–31). Previously, Green et al. utilised multidimensional 151 152 Grade of Membership (GoM) clustering with nine cognitive measures to derive subgroups of cognitive performance in the ASRB (28). The most parsimonious configuration were two 153 clusters of schizophrenia cases termed cognitive deficit (CD), with more pervasive cognitive 154 155 impairment, and cognitively spared (CS), displaying intermediate cognitive performance 156 relative to CD cases and healthy controls. Polygenic scores (PGS) were constructed for the 25 biochemical traits correlated with either schizophrenia or cognitive ability in a genotyped 157 158 subset of the ASRB with schizophrenia cases subtyped as CD or CS (N = 391, Supplementary materials). The full details of this cohort and the generation of PGS is described in the 159 supplementary text. We tested the association of each biochemical PGS with CD status using 160 161 binomial logistic regression covaried for sex and the first three SNP-derived principal components (Supplementary Materials). The variance explained (Nagelkerke's R^2) in the full 162 163 model with the PGS versus the null (covariates and intercept only) model, was converted to the liability scale assuming a population prevalence for CD of 0.33% (32). The population 164 prevalence for CD is somewhat arbitrary, however, given the population prevalence of 165 schizophrenia is around 0.7%, and 43% of this portion of the schizophrenia cases in the ASRB 166 cohort was subtyped as CD, we believe this was an appropriate value to select. A polygenic 167 score for general cognitive ability and a schizophrenia polygenic risk score (PRS) was also 168 169 derived in this cohort for comparison (Supplementary Materials).

170

171 Latent causal variable models

Genetic correlation may reveal important insights into shared biology between two traits,
however, this should not be interpreted as implying a causal relationship in either direction. To
evaluate evidence for a causal relationship, we implemented the latent causal variable (LCV)

model to estimate genetic causality between traits, as outlined extensively elsewhere (9,33). 175 The LCV framework leverages the bivariate genome-wide distribution of marginal SNP effects 176 177 on both traits to estimate *partial genetic causality*. Specifically, the LCV assumes a latent variable, L, mediates the genetic correlation between the traits, and tests the strength of the 178 correlation of each trait with L. The mixed fourth moments (cokurtosis) of marginal effect sizes 179 180 for each trait (Z_1, Z_2) are compared to evaluate the proportionality of effects on either trait. The main output of the LCV model is the posterior mean genetic causality proportion (\widehat{GCP}), 181 whereby $\widehat{GCP} > 0$ implies partial genetic causality of trait one on trait two, and vice versa. In 182 other words, given $\widehat{GCP} > 0$, then trait one SNP effects (Z_1^2) tend to be proportionally large on 183 trait two (Z_1Z_2) , such that $|E(Z_1^2 Z_1Z_2)| \ge |E(Z_2^2 Z_1Z_2)|$. As in LDSR, the LDSR intercept 184 is utilised here to guard against inflation due to sample overlap. We defined *partial genetic* 185 *causality* using the recommended threshold of a significantly non-zero $|\widehat{GCP}| > 0.6$, as this was 186 shown by O'Connor and Price in simulations to guard against false positives (9). An LCV 187 model was constructed for all genetically correlated psychiatric-biochemical trait pairs. Weak 188 189 GCP estimates close to zero for genetically correlated traits imply that their relationship is 190 potentially mediated by horizontal pleiotropy, whereby there are shared pathways, but the two traits do not likely exhibit vertical pleiotropy by acting within the same pathway. We also 191 attempted to replicate the observed \widehat{GCP} using a non-UKBB biochemical GWAS (34–37). It 192 should be noted that the posterior mean \widehat{GCP} is not an estimate of the magnitude of any 193 potential causal relationship and should not be interpreted as such - rather it evaluates the 194 strength of evidence for a putative causal relationship using genome-wide SNP effects. The 195 196 scripts to construct an LCV model are available from (https://github.com/lukejoconnor/LCV). 197

198

200 Mendelian randomisation

C-reactive protein (CRP) exhibited strong evidence of partial genetic causality on multiple 201 202 psychiatric disorders, and thus, we sought to estimate the magnitude of this causal relationship 203 using univariable and multivariable Mendelian randomisation (MR). A detailed description of the MR methodology in this study is provided in the supplementary materials. MR is different 204 from the LCV approach in that it leverages independent SNPs strongly associated with trait 205 206 one (the exposure trait) as instrumental variables (IVs) to estimate the effect of the exposure 207 on an outcome. The theoretical justification for using SNPs as IVs has been discussed 208 extensively previously (8,38). We estimated the total effect of CRP on each disorder using independent genome-wide significant SNPs from a smaller non-UKBB GWAS as sample 209 overlap between exposure and outcome can bias MR estimates (Supplementary Materials) (34). 210 211 The *F*-statistic for IVs for this CRP GWAS was sufficiently strong (*F*-statistic > 10), as reported previously (34). 212

213

Our primary model was an inverse-variance weighted effect (IVW) estimator with 214 215 multiplicative random effects, which assumes all IVs are valid and is less biased by heterogeneity than a fixed-effects IVW estimator (8). Whilst the IVW estimator is generally 216 217 considered the most well-powered approach, the assumption that all IVs are valid is probably unrealistic in practice. As a result, we implemented a series of models which make different 218 219 underlying assumptions regarding IV validity. Specifically, median based estimators which 220 assume the majority of IVs are valid (39); a weighted mode estimator and a contamination mixture model, that both assume out of groups of IVs having the same asymptotic estimate, 221 222 the largest group will be comprised of valid IVs (plurality valid) (40,41); and MR-Egger, which includes a non-zero intercept as a test of the average pleiotropic effect and assumes that there 223 is no significant correlation between direct IV effects on the outcome and genetic association 224

of IVs with the exposure (Instrument Strength Independent of Direct Effect (InSIDE) 225 assumption) (42). As recommended by Bowden *et al.*, we ensured that the l^2 statistic of IV-226 227 exposure effects exceeded 0.9, as this assesses the relative strength of the no-measurement error assumption, and thus, the suitability of using an MR-Egger model (43). We also tested 228 the effect of using robust regression and penalised estimates for heterogeneity on the IVW, 229 230 median, and Egger regression estimates (44). Evidence of horizontal pleiotropy and outliers 231 were further investigated by testing heterogeneity in the IV/exposure-outcome effects (45), performing a leave-one-IV out analysis (38), testing for a non-zero MR Egger intercept (42), 232 233 and an MR PRESSO test of global pleiotropy (also related to heterogeneity) (46). Furthermore, we also tested whether there was evidence of a causal effect in the reverse direction (psychiatric 234 disorder as exposure), although MR estimates with binary exposures should be treated 235 236 cautiously, as described elsewhere (47,48). Given only approximately 2,000,000 SNPs were available in the non-UKBB CRP GWAS utilised, we utilised the more deeply imputed UKBB 237 CRP GWAS as the outcome here, although these results could therefore be inflated by sample 238 overlap for AN and MDD. 239

240

Multivariable MR (MVMR) was then performed to evaluate the direct effect of CRP on each 241 psychiatric outcome tested when conditioned on BMI and interleukin six (IL-6) signalling, 242 which are both postulated to be closely functionally related to circulating CRP (Supplementary 243 244 Text) (49,50). MVMR assumes that IVs are strongly associated with at least one exposure, and 245 therefore, SNPs were chosen which were genome-wide significant for at least one phenotype. We constructed an IL-6 and BMI multivariable model separately – that is CRP conditioned on 246 247 circulating IL-6 and its receptor (IL6R), and CRP conditioned on BMI, as well as BMI and IL-6R. The strength of the IVs in each multivariable model was assessed using a two-sample 248 conditional F statistic – which tests whether the IVs strongly predict each exposure, conditional 249

250 on the other exposures in the model (51,52). When an F statistic > 10 could not be achieved, we relaxed the SNP inclusion threshold to represent suggestive significance in the GWAS 251 $(P_{\rm GWAS} < 1 \times 10^{-5})$, Supplementary Text). We compared direct estimates for each exposure using 252 four different MVMR models – an IVW MVMR estimator, a median based MVMR estimator, 253 an Egger regression based MVMR estimator, and a regularisation approach whereby LASSO 254 255 type penalisation is applied to shrink intercept terms corresponding to IVs predicted as valid 256 (MVMR-LASSO) (53). Given that CRP was genetically correlated with several psychiatric 257 GWAS, genetic correlation may result in bias in MR estimates (9). However, MR is a valuable 258 extension to the LCV model as it allows for specification of several different assumptions about 259 IV validity and facilitates the estimate of total (univariable MR) and direct (MVMR) effects. The MR analyses were performed using the following packages in R version 3.6.0 -260 TwoSampleMR v 0.5.5 (54), MendelianRandomization v 0.5 (55), MRPRESSO v 1.0 (46), 261 and MVMR v 0.3 (51). 262

263

264 Genetic overlap between C-reactive protein and schizophrenia

We investigated whether any of the lead SNPs (genome-wide significant) reported in the PGC3 265 SZ GWAS were also associated with CRP ($P < 5 \ge 10^{-8}$). For overlapping genome-wide 266 significant signals, we tested whether there was a shared causal variant or different causal 267 variants underlying these loci, assuming a single causal variant, using the coloc package 268 269 colocalisation method (56). Moreover, utilised ρ -HESS we 270 (https://github.com/huwenboshi/hess) to estimate local genetic covariance between SZ and CRP, as opposed to a genome-wide estimate by LDSR, with local genetic covariance ($\rho_{g,local}$) 271 calculated for munged HapMap3 SNPs in around 1,600 approximately independent LD blocks 272 273 outside the MHC (57,58). Genes within the five LD blocks with the most statistically 274 significant subjected g:Profiler to pathway analysis using were $\rho_{g,local}$

275	(<u>https://biit.cs.ut.ee/gprofiler/gost</u>) (59). We derived an estimate of genetic correlation ($r_{g,local}$)
276	by dividing $\rho_{g,local}$ by the product of the square roots of CRP and SZ local heritability per LD
277	block, respectively.
278	
279	Downstream effects of C-reactive protein
280	We investigated the downstream effect of CRP on circulating levels of 3284 proteins in blood
281	using MR (60). We used the larger UKBB CRP GWAS to select IVs to maximise power. The
282	principal MR model was the IVW estimator with multiplicative random effects to maximise
283	power. Proteins which demonstrated at least nominal association with CRP levels after multiple
284	testing correction (FDR < 0.1) were investigated for protein-protein interaction and
285	overrepresentation in biological pathways using STRING v 11.0 (61).
286	
287	
288	
289	
290	
291	
292	
293	
294	
295	
296	
297	
298	
299	

300 **RESULTS**

Widespread genetic correlation between blood-based biomarkers and psychiatric traits 301

We tested the genetic correlation between a panel of blood-based biomarkers and 10 302 psychiatric GWAS using LDSR. Interestingly, we found that 61% (N = 30) of the biochemical 303 304 traits tested were significantly correlated with at least one psychiatric trait after multiple-testing correction, with every psychiatric trait exhibiting a significantly non-zero biochemical 305 306 correlation after correction except for Tourette's syndrome (Figure 1a, Supplementary Tables 2-11) The most significantly correlated biomarker for each trait is outlined in table 1. 307

308

Table 1: The most significant genetic correlation between each trait and a biochemical 309

GWAS 310

Biochemical trait	Psychiatric trait ¹	r_g^2	SE	Р
High light scatter reticulocyte percentage	ADHD	0.256	0.033	4.58 x 10 ⁻¹⁵
High light scatter reticulocyte count	OCD	-0.212	0.046	3.37 x 10 ⁻⁶
C-reactive protein	AN	-0.286	0.038	9.76 x 10 ⁻¹⁴
Vitamin D	ASD	-0.177	0.047	2 x 10 ⁻⁴
Creatinine	BIP	-0.106	0.027	7.23 x 10 ⁻⁵
Leukocyte count	Cognition	-0.198	0.024	2.66 x 10 ⁻¹⁶
Leukocyte count	MDD	0.155	0.025	9.77 x 10 ⁻¹⁰
Leukocyte count	PTSD	0.225	0.043	1.37 x 10 ⁻⁷
Lymphocyte count	SZ	0.075	0.017	1.52 x 10 ⁻⁵
Lymphocyte count	TS	-0.093	0.039	0.017

¹Psychiatric GWAS: attention/deficit hyperactivity disorder (ADHD), anorexia nervosa (AN), autism 311 312 spectrum disorder (ASD), bipolar disorder (BIP), major depressive disorder (MDD), obsessive 313 compulsive disorder (OCD), post-traumatic stress disorder (PTSD), schizophrenia (SZ), and Tourette's 314 syndrome (TS).

315 ${}^{2}r_{g}$ is the estimate of genetic correlation from LDSR

316

There was clear evidence of biomarkers with divergent genetic correlations between different 317 psychiatric phenotypes – for instance, CRP, alanine aminotransferase (ALT), and sex-hormone 318 binding globulin (SHBG, Figure 1b). In the case of CRP, it displayed a negative correlation 319 after correction with OCD, AN, and cognition, as well as a trend towards a negative correlation 320 with schizophrenia ($P = 1.7 \times 10^{-3}$), whilst its correlation with PTSD, MDD, and ADHD was 321 strongly positive. These data provide some support to recent cohort studies, including lower 322 CRP observed in patients with eating disorder (62), whilst elevated CRP was associated with 323 324 ADHD (63). Notably, this contradicts previous observational estimates of elevated CRP in 325 schizophrenia (64). Moreover, there were 14 biochemical traits which were only correlated after multiple testing correction with two or fewer psychiatric GWAS. A few such of examples 326 of these more specific correlations included albumin and ADHD ($r_g = -0.151$), mean 327 corpuscular volume and AN ($r_g = 0.087$), mean sphered cell volume and SZ ($r_g = 0.06$), and 328 creatinine with BIP and SZ (SZ: $r_q = -0.07$, BIP: $r_q = -0.106$). 329

330

We further investigated the relationship between the profile of 49 LDSR biochemical Z scores 331 332 for each psychiatric trait. We observed strong positive and negative correlations between the trait-wise LDSR biochemical Z for each trait, which we term the biochemical correlation 333 profile (Figure 1c). For instance, the ADHD biochemical correlation profile demonstrates large 334 335 magnitude positive correlations with ASD, MDD, and PTSD but negative correlations with 336 OCD, AN, and Cognition. This can be interpreted as traits which tend to be positively 337 correlated with ADHD are also positively correlated with ASD, MDD, and PTSD and vice 338 versa for OCD, AN, and Cognition. These relationships were further interrogated by subjecting 339 the 10 biochemical correlation profiles to finite Gaussian mixture modelling (GMM, Figure

340	1d). We observed five components (clusters) with diagonal distribution, variable volume, and
341	equal shape as the most parsimonious parameterisation of the covariance matrix
342	(Supplementary Table 12). The biochemical correlation profile LDSR Z within each cluster are
343	plotted in figure 1e. Briefly, the first component was composed of a series of traits with
344	discordant correlations between the disorders, such as CRP, ALT, and glycaeted haemoglobin
345	(HbA1c), whilst the second and third component were a diverse set of biomarkers with more
346	similar LDSR Z across the psychiatric disorders tested. Component four was notable as it was
347	solely composed of reticulocyte (immature erythrocytes) related traits, which analogous to
348	component one was quite discordant in its correlation profiles. The fifth and final component
349	was composed of other erythrocytic related traits, however, the differences between disorders
350	were less marked than component four. Taken together, this demonstrates that groups of
351	biomarkers tend to have similar relationships with different psychiatric traits.
352	
353	
354	
355	
356	
357	
358	
359	
360	
361	
362	
363	
364	



386	Figure 1. Genetic correlation between blood-based biomarkers and psychiatric
387	GWAS . (a) Heatmap of LDSR correlation Z scores (r_g /standard error) between each
388	psychiatric trait and 49 biochemical GWAS. The psychiatric and biochemical traits
389	are grouped on the x and y axes, respectively, by hierachial clustering using Pearson's
390	distance. (b) Examples of biochemical traits with evidence of discordant genetic
391	correlations amongst the different psychiatric phenotypes. C-reactive protein (CRP),
392	alanine aminotransferase (ALT), and sex-hormone binding globulin (SHBG) are
393	presented for illustration. The forest plot denotes the LDSR r_g with its standard error
394	representing the confidence bars. Traits highlighted in blue, orange, and red, for CRP,
395	ALT, and SHBG, respectively, were significantly correlated after the application of
396	multiple testing correction. (c) Correlation matrix (Pearson) of LDSR Z between each
397	trait, correlation estimates that survive correction for the number of tests performed
398	are highlighted. (d) Components of biochemical LDSR Z scores derived using finite
399	Gaussian mixture modelling (GMM) - the optimal parametrisation of the variance-
400	covariance matrix was five components with diagonal distribution, variable volume,
401	and equal shape (VEI). The components are plotted relative to their contribution to
402	the first and second principal component of the LDSR Z matrix. (e) Box-and-whisker
403	plots of the LDSR Z for each disorder composed of traits assigned to each of the five
404	components derived from the GMM procedure.
405	
406	
407	

- 408
- 409

410 Genetically proxied biochemical measures were associated with a severe cognitive

411 deficit schizophrenia subtype

We tested the association between 25 genetically proxied biomarkers (polygenic scores – PGS) 412 that were correlated with either the schizophrenia or general cognitive ability GWAS and a 413 severe cognitive deficit subtype of schizophrenia (Cognitive Deficit - CD) and a subset of cases 414 with less marked impairment (Cognitively Spared - CS). There were two biochemical PGS 415 416 that displayed a relatively significant association with CD status - haematocrit percentage and immature reticulocyte faction (Figure 2, Supplementary Table 13). Each standard deviation 417 418 increase in the immature reticulocyte fraction PGS was associated with a 35.7% (95% CI: 14.5%, 56.9%, $P = 4.72 \times 10^{-3}$, q = 0.07) increase in the odds of severe cognitive deficit. 419 Conversely, genetically proxied haemtocrit percentage exerted a protective effect -OR = 0.744420 421 $[95\% \text{ CI: } 0.533, 0.954], P = 5.82 \times 10^{-3}, q = 0.07$. We emphasise that these signals only survive 422 multiple testing correction using a lenient false-discovery rate (FDR) threshold of 10%, however, given the small sample size of this cohort, we believe that these findings remain 423 noteworthy. Immature reticulocyte fraction was negatively correlated with cognition, with a 424 trend towards a negative relationship with schizophrenia as well. Interestingly, haemtocrit 425 percentage was also negatively correlated with cognition, however, there was a depletion of 426 427 haemtocrit percentage alleles amongst CD vs CD schizophrenia cases, suggesting a more 428 complex relationship may be present. Both the haemtocrit and reticulocyte fraction PGS explained around 1% of phenotypic variance in CD on the liability scale, which is similar to a 429 430 PGS for general cognitive ability (Figure 2). A model constructed with all nominally CDassociated PGS (P < 0.05) explained almost 3% in phenotypic variance. There was a non-431 432 significant trend of enrichment of schizophrenia PRS (P = 0.054) in CD. Whilst these values are modest, it does suggest that the genetic architecture of biochemical traits is correlated with 433 the severity of cognitive impairment in schizophrenia. 434





Figure 2. The association between biochemical polygenic scores and a severe cognitive deficit subtype of schizophrenia. Left panel is a forest plot of the association (odds ratio with 95% confidence interval) between a standard deviation increase in each polygenic score (PGS) a severe cognitive deficit (CD), relative to schizophrenia cases with less marked impairment (CS). The right panel is the variance explained on the liability scale (Nagelkerke's R^2 , assuming an 0.33% CD population prevalence) for biochemical and a general cognitive ability PGS.

444

445 Strong evidence of partial genetic causality between blood-based biomarkers and

446 neuropsychiatric illness

A latent causal variable (LCV) model was constructed between each significantly correlated 447 biochemical-psychiatric trait pair to estimate partial genetic causality ($|\widehat{GCP}| > 0.6$ as strong 448 evidence of partial genetic causality). We can then infer the consequence of the partial genetic 449 causality of one trait on another using the sign of the genetic correlation. There were five 450 instances where we found strong evidence of a potential causal relationship, with all of them 451 452 suggesting an effect of the biochemical measure on the psychiatric trait, rather than vice versa (Table 2, Supplementary table 14). These were as follows: glucose on ADHD ($\widehat{GCP} = 0.64$), 453 CRP on AN ($\widehat{GCP} = 0.92$), urate on cognition ($\widehat{GCP} = 0.88$), CRP on MDD ($\widehat{GCP} = 0.62$), and 454

CRP on OCD ($\widehat{GCP} = 0.75$). It is important to emphasise that these posterior mean \widehat{GCP} are not 455 magnitudes of causal effect and only imply that there is a causal relationship between the 456 biochemical traits and the psychiatric phenotype. Given the sign of the genetic correlation, we 457 can likely infer that glucose may increase the risk of ADHD and urate could have a deleterious 458 effect on general cognitive function. As outlined in a previous section, CRP has highly 459 460 divergent correlations, and these data coupled with the LDSR further support a protective effect on AN and OCD, whilst it is likely risk increasing for MDD. SZ did not quite survive multiple-461 462 testing correction for a genetic correlation with CRP, however, given previous evidence of a protective effect of CRP on SZ from MR studies (65-67), we also constructed an LCV model 463 between CRP and SZ and found moderate support for this relationship ($\widehat{GCP} = 0.56$, SE = 0.23, 464 $P = 5.11 \times 10^{-6}$). Given the genetic correlation is only small it is less likely that previous MR 465 466 studies were unduly biased by genetic correlation. In addition, we also observed an unusual phenomenon in the HbA1c and PTSD model, whereby the posterior mean \widehat{GCP} was strongly 467 468 positive ($\widehat{GCP} = 0.76$), implying an effect of HbA1c on PTSD, whilst its Z score was negative (Z = -6.51), which signifies the opposite. As described in the supplementary material and 469 supplementary figure 1, we found that these conflicting data was likely attributable to a rare 470 violation of the LCV model assumptions, whereby the mixed fourth moments had opposite 471 signs to each other and the genetic correlation. This could be explained by certain SNPs having 472 473 highly divergent effects from the rest of the genome-wide signal. Moreover, there were two other trait pairs that trended towards partial genetic causation ($|\widehat{GCP}| > 0.5$) but did not exceed 474 the stringent 0.6 threshold. These were SHBG on cognition ($\widehat{GCP} = 0.55$) and triglycerides on 475 OCD ($\widehat{GCP} = 0.55$). We then sought to replicate the LCV findings by utilising different 476 previously published GWAS for glucose, urate, CRP, and HbA1c. Despite smaller sample 477 478 sizes, we found relatively consistent GCP estimates which supported the above models using 479 the UKBB GWAS (supplementary table 14). The exception to this was HbA1c, which did not

- 480 show strong evidence of partial genetic causality ($\widehat{GCP} = 0.13$) using a smaller sample size
- 481 GWAS by Wheeler *et al.* (37).
- 482

483 Table 2: Strong evidence of partial genetic causality of a biochemical measure on a

484 psychiatric trait

Biochemical trait	Psychiatric trait ¹	GCP ²	SE	P^3	rg
Glucose	ADHD	0.64	0.28	0.035	0.134
C-reactive protein	AN	0.92	0.07	5.95 x 10 ⁻⁵⁶	-0.286
C-reactive protein	MDD	0.62	0.21	1.57 x 10 ⁻¹²	0.154
C-reactive protein	OCD	0.75	0.16	2.07 x 10 ⁻¹⁸	-0.201
Urate	Cognition	0.88	0.09	5.27 x 10 ⁻¹¹⁴	-0.1047

¹Psychiatric GWAS: attention/deficit hyperactivity disorder (ADHD), anorexia nervosa (AN), major
depressive disorder (MDD), and obsessive-compulsive disorder (OCD).

487 ²The posterior mean genetic causality proportion (GCP), with its accompanying posterior standard error

488 in the adjacent column.

489 ${}^{3}P$ value which tests whether the GCP estimate is significantly different from zero.

490

491 C-reactive protein levels exert a direct protective effect on schizophrenia conditioned on

492 body mass index and interleukin-6 signalling

493 CRP displayed strong evidence of partial genetic causality on three psychiatric disorders, and 494 thus, we sought to further analyse these relationships by estimating total effects and direct 495 impact of CRP using univariable and multivariable Mendelian randomisation (MR), 496 respectively (Supplementary Tables 16-22). We included SZ in these analyses, due to evidence 497 from previous SZ GWAS that CRP exerts a protective effect on schizophrenia liability, as 498 discussed in the previous section. The CRP GWAS utilised here was drawn from a non-UKBB 499 cohort such that there was no sample overlap with the AN and MDD GWAS (Supplementary

500 Materials) (34). Using our primary model (IVW estimator with multiplicative random effects), we found evidence that a natural log transformed mg/L increase in CRP was associated with a 501 statistically significant reduction in the odds of SZ (OR = 0.91 [95% CI: 0.85, 0.98], P = 0.01) 502 and AN (OR = 0.91 [95% CI: 0.83, 0.99], P = 0.03), which supports the LDSR inferred direction 503 504 of the LCV relationship. Using a less conservative IVW estimator with fixed effects yielded a more precise estimate in both instances, as expected (CRP \rightarrow SZ $P = 6.29 \times 10^{-5}$, CRP \rightarrow AN 505 $P = 9.79 \text{ x } 10^{-3}$). There was a trend towards an odds increasing effect of CRP on MDD (P =506 0.19), whilst there was no indication of a reliable effect in the OCD model (P = 0.82). It should 507 508 be noted that as MR exploits independent (relative linkage equilibrium) genome-wide 509 significant variants as IVs, as opposed to using genome-wide marginal effects in the LCV approach, and thus, a non-significant estimate from MR does not necessarily preclude the 510 existence of a causal relationship, although LCV models with corresponding MR support 511 would perhaps be viewed as stronger evidence. We discuss the sensitivity analyses for each of 512 513 these univariable models in detail in the supplementary text. Briefly, the five MR tests deployed 514 with different assumptions regarding IV validity (plurality valid, majority valid, and InSIDE assumption) had very similar point estimates (OR range: 0.88-0.91) and were all statistically 515 516 significant for CRP \rightarrow SZ with the exception of the simple median (P = 0.07). The CRP \rightarrow AN estimate across the different models were also directionally consistent, however, they were not 517 statistically significant (except for some contamination mixture models with different 518 prespecified standard deviation of invalid IVs), and thus, the total effect of CRP on AN by MR 519 has comparatively weaker evidence compared to SZ. The effect of using robust, penalised, or 520 521 robust penalised weights in the median, IVW, and Egger models was not marked for each of the CRP psychiatric models (Figure 3a, Supplementary Table 21). In the CRP \rightarrow SZ and CRP 522 \rightarrow AN model, the Egger intercept was not significantly different than zero (although there was 523 a trend in the AN model, P = 0.07), and thus, there was no strong statistical evidence of 524

525 confounding pleiotropy using this metric. However, there was evidence of heterogeneity between the IV ratio estimates for AN and SZ: the MR PRESSO global test of pleiotropy was 526 527 significant and Cochran's *Q* statistic significant for AN and SZ, although both causal estimates remained statistically significant in the MR-PRESSO outlier corrected estimates 528 529 (Supplementary table 19). Given the biological complexity of these phenotypes, heterogeneity does not necessarily imply confounding pleiotropy. Moreover, using a leave-one-out-analysis, 530 531 we found evidence of one outlier IV in the SZ model, whilst there were three outlier SNPs in the AN model (Supplementary Table 20), although the effects of removing these IVs were 532 533 relatively small. The outlier IV in the SZ model was also proximal to the CRP gene itself (IVW 534 P = 0.07 when removed), meaning it is likely to influence SZ through CRP, rather than being indicative of confounding pleiotropy. Given the CRP estimates on AN and SZ remained 535 536 significant removing outliers by MR PRESSO or through iterative single IV exclusion, it is 537 less likely that horizontal pleiotropy fully explains these signals. There was also no evidence using a reverse MR model, with the psychiatric disorder as the exposure, that there were 538 539 bidirectional effects, although these models are inherently underpowered and are best treated 540 as a test of the null hypothesis only (Supplementary Table 22).







MDD, OCD, and SZ. (b) Direct effect of CRP in multivariable MR models – the three
models contained the following phenotypes as additional exposures: i) circulating
interleukin 6 (IL6) and its receptor (IL6R), body mass index (BMI), and IL6R and
BMI.

551

We sought to investigate the direct effect of circulating CRP on the above psychiatric 552 553 phenotypes using multivariable Mendelian randomisation (MVMR) conditioning on IL-6 signalling and BMI. We found that CRP exhibited a robust direct protective effect on 554 555 schizophrenia conditioned on IL-6 signalling and BMI (Supplementary table 23, Figure 3b). For instance, using a multivariable IVW estimator, the direct effect of CRP on schizophrenia 556 conditioned on BMI and IL-6R was analogous to the univariable IVW total estimate (OR = 557 0.88 [95% CI: 0.79, 0.98], P = 0.01). There was no evidence of an effect of BMI or IL-6 558 signalling on schizophrenia conditioned on CRP. Similarly, the effect size of the CRP \rightarrow AN 559 560 MVMR models remained similar to that estimated in the univariable constructs (Figure 3b), 561 however, these estimates were only statistically significant in a subset of the models (Supplementary table 23). As a result, the MR evidence for the direct protective effect of CRP 562 563 on AN is comparatively weaker than the CRP \rightarrow SZ model, as was seen in the univariable estimates. We also observed some evidence to suggest that IL-6 abundance exerts a protective 564 effect on AN conditional on CRP and IL-6R, which was nominally non-zero in every MVMR 565 model except for the median estimator (OR = 0.96 [95% CI: 0.93, 0.99] per unit increase in 566 IL-6, P = 0.037 – multivariable IVW-multiplicative random effects). Interestingly, whilst 567 568 evidence for a direct effect of CRP on MDD conditioned on each variable set was weak (Figure 3b, Supplementary Table 23), there was consistent evidence that elevated IL-6R was associated 569 570 with increased odds of MDD conditioned on CRP and IL-6 or CRP and BMI. For example, 571 each unit increase in blood IL-6R protein expression was estimated to increase the odds of 572 MDD by 2.7% [95% CI: 0.6%, 4.9%] conditioned on CRP and BMI. Finally, there was no 573 evidence in the MVMR models to support the protective effect of CRP on OCD, however, 574 there was evidence that increased BMI decreases the odds of OCD conditioned on CRP and 575 IL-6 signalling (Supplementary Table 23). This BMI \rightarrow OCD effect estimate was quite large, 576 albeit with wide confidence intervals – OCD OR per SD increase in BMI conditioned on CRP 577 and IL-6R = 0.52 [95% CI: 0.14, 0.91], $P = 1 \ge 10^{-3}$.

578

579 C-reactive protein displays overlapping association signals with schizophrenia and may 580 have downstream impacts on the brain

There were five schizophrenia GWAS lead SNPs ($P < 5 \ge 10^{-8}$), that also obtained genome-581 wide significance in the UKBB CRP GWAS. Colocalisation analyses using the European only 582 subset of the SZ GWAS demonstrated strong evidence for the association of three of these loci 583 with both SZ and CRP, however, there was likely a different underlying causal variant 584 585 (Supplementary Table 24, Supplementary Text, Supplementary Figure 2). Local genetic 586 correlation estimates with ρ -HESS demonstrated that 13 of the LD block partitions of the human genome displayed non-zero local covariance between CRP and SZ (Supplementary 587 588 Table 25, Supplementary Figure 3) after Bonferroni correction. Interestingly, five of these LD blocks with strong evidence of local genetic covariance were positive, and thus, for these 589 590 regions of the genome SZ and CRP were positively correlated in contrast to the genome-wide 591 estimate of nominal negative correlation. We investigated the pathways overrepresented for genes physically mapped to the LD blocks of the top five most significant $r_{g,local}$ estimates 592 (Supplementary Table 27). Interestingly, we found that *retinol metabolism* was the most 593 594 significantly overrepresented gene-set after multiple testing correction, which is notable given evidence that retinoids play a role in the pathogenesis of SZ (30,68). 595

597 We also sought to investigate the downstream consequences of raised CRP. We estimated the effect of raised CRP on the expression of 3284 proteins in blood using univariable MR. Using 598 599 a liberal FDR cut-off of 10%, we found that 95 proteins were putatively causally influenced by 600 elevated CRP, with 45 of these proteins surviving a stricter FDR threshold of 5% (Supplementary Table 28). We emphasise that these analyses are exploratory in nature and we 601 treat the effect sizes of the CRP effect on each protein largely as a test of the null hypothesis 602 603 that the two are not associated. The vast majority of proteins prioritised using the IVW estimator were directionally consistent in the median, mode, and Egger sensitivity analyses 604 605 (Supplementary Table 29). However, 20 of the FDR < 0.1 proteins were suggested to act in the 606 opposite direction and causally influence CRP as the estimated variance explained by the IVs was significantly larger in the outcome than the CRP exposure, although this does not rule out 607 608 bidirectional effects (Supplementary Table 30). We found that these proteins putatively 609 influenced by CRP were enriched in several pathways including glycaemic signalling and 610 lymphocyte biology (Supplementary Tables 31-33). Notably, there were neuronal pathways 611 overrepresented with CRP-associated proteins - including, axon guidance, dopaminergic 612 synapse, neurogenesis, glial cell differentiation, and cholinergic synapse. For example, dopaminergic and cholinergic synapse overrepresentations were driven by the three genes 613 614 (AKT1, AKT2, and AKT3) that encode the RAC-alpha/beta/gamma serine/threonine-protein 615 kinase complex, which was measured as a single entity in the protein study. Collectively, these 616 data provide preliminary evidence that CRP may influence the expression of neuronally 617 relevant proteins, and subsequent studies should seek to investigate these associations and their significance for different psychiatric phenotypes. 618

619

620

622 **DISCUSSION**

In this study, we investigated genetic correlation and causality between a diverse panel of 623 biochemical traits and psychiatric disorders, as well as general cognitive ability and a cognitive 624 deficit subtype of schizophrenia. Our data demonstrated that there is clear evidence of genetic 625 overlap between blood-based measures and psychiatric phenotypes, as quantified by LDSR, 626 627 which is likely indicative of shared variants and pathways that predispose to these traits. 628 Interestingly, the distribution of biochemical-psychiatric correlations demonstrated traits often 629 exhibited highly divergent correlations (different signs), as well as clusters of biochemical 630 measures that tended to have similar psychiatric correlation profiles. For instance, we found that five reticulocyte traits clustered together (Figure 1e), and they tended to have opposing 631 psychiatric correlations (strong positive correlation with ADHD, MDD, and PTSD, whilst 632 negative correlations with AN, OCD, SZ, and cognition). The genetic architecture of 633 reticulocyte related traits remains relatively uncharacterised, however, it is a highly polygenic 634 635 trait that also has demonstrated genome-wide significant associations with rare nonsynonymous variation in genes such as SPTA1, E2F4, and IFRD2 (69,70). Future study should 636 further investigate how the genetic factors which contribute to reticulocyte biology may also 637 influence psychiatric traits. Given the LCV posterior mean GCP estimates between the 638 genetically correlated reticulocyte traits and each psychiatric phenotype were low, it suggests 639 640 the existence of horizontal rather than vertical pleiotropy.

641

A key advantage of our study is that we extended the findings from the LDSR models to estimate which biochemical-psychiatric trait pairs may represent causal relationships. We caution that all of these findings require validation in well-powered, replicated, randomised controlled trials to confirm that the causal effects do indeed exist. The putative effect of urate and glucose on cognition and ADHD, respectively, may have direct implications for drug

647 repurposing given that compounds which modulate these traits are readily available. Both of 648 these relationships are also supported by previous observational data (71–73). Indeed, data 649 from an incident cohort study which treated individuals with urate lowering compounds 650 allopurinol and febuxostat demonstrated evidence of a risk decreasing effect on dementia, 651 supporting the deleterious effect of urate on general cognitive function (74).

652

653 The inferred effect of CRP on different psychiatric disorders was particularly interesting given 654 that there was evidence of an odds-decreasing effect on AN, OCD, and SZ, whilst the opposite 655 is true for MDD. CRP is traditionally conceptualised as a biomarker of chronic inflammation; however, its biology is likely somewhat more complex given it is also implicated to play a 656 direct role in pathogen response (75,76). Moreover, as reviewed by Del Giudice and 657 658 Gangestad, CRP in its hepatically secreted pentameric isoform demonstrates some antiinflammatory effects and may be a marker of other non-inflammatory states (77). In our study, 659 660 we also provide evidence that CRP levels may also exert an effect on proteins with neurological significance, including proteins enriched in pathways relevant to psychiatric illness such as 661 axon guidance. Moreover, we show for the first time the previously documented protective 662 effect of CRP on SZ through MR is not likely attributable to the effect of BMI and IL-6 663 signalling, which are closely related variables to CRP. Data from our study and previous 664 examinations of the relationship between CRP and SZ through MR seemingly contradict 665 666 previous observational evidence that CRP is elevated in SZ (64,78). If we assume that there is 667 a causal effect, there are a number of explanations that could account for this, although all require further investigation. Firstly, previous observational studies that directly measured 668 669 CRP in case/control cohorts could be confounded due to a variety of variables including lifestyle and general health, or even be caused by factors related to psychosis and/or 670 schizophrenia itself. Whilst there was no evidence in this study using the LCV model or reverse 671

MR that SZ causally influences CRP levels, local significant estimates of positive and negative 672 673 genetic correlation between SZ and CRP observed for several LD blocks suggests a complex 674 interrelationship between these phenotypes may exist that warrants further study. Secondly, CRP itself may influence factors that impact the brain, directly or indirectly, and these factors 675 may play a role in the pathogenesis of psychiatric illness. For instance, CRP was postulated in 676 677 this study to causally upregulate the expression of the RAC-alpha/beta/gamma 678 serine/threonine-protein kinase complex (AKT1, AKT2, and AKT3), with impaired signalling by these serine/threonine kinases implicated to dysregulate dopaminergic neurotransmission 679 680 and downregulation of genetically predicted neuronal AKT3 expression associated with SZ via a transcriptome-wide association study (23,79). Finally, given that infection has been 681 associated with liability of SZ, the role of CRP in pathogen defence may contribute to its 682 683 putative protective properties. Further study on the neurobiological consequences of CRP signalling and its role in SZ is warranted, particularly to reconcile the discrepancies between 684 observational studies and MR. 685

686

The putative causal effect of CRP on AN was demonstrated in this study is, to our knowledge, 687 a novel finding; however, it does support data from a recent longitudinal study which 688 689 demonstrated that elevated CRP was associated with a protective effect on eating disorders 690 (62), along with decreased measured CRP observed specifically in AN (80). It should be noted 691 that whilst the LCV data supported strong partial genetic causality of CRP on AN, the MR 692 evidence was less statistically significant, with some evidence in the MVMR that IL-6 signalling may exert a protective effect on AN conditioned-on CRP. Inhibition of the IL-6 693 pathway has been associated with weight gain which may be protective for AN (81). 694 695 Furthermore, CRP likely is intertwined with other metabolic factors, including insulin signalling, which our group has previously shown through MR is also putatively protective for 696

AN (48). In MDD, we found some evidence to support that upregulation of the IL-6 receptor 697 may be risk increasing conditioned on CRP and BMI, supporting preliminary data that 698 699 blockade of IL-6R by agents like tocilizumab may improve depressive symptoms (82). 700 However, data related to the anti-depressant qualities of tocilizumab are conflicting (83), and randomised control trials are warranted to further investigate repurposing opportunities for IL-701 702 6 inhibition in MDD. Finally, BMI demonstrated a quite robust protective effect on OCD 703 conditioned on CRP and IL-6 signalling, in accordance with observational data that OCD is 704 associated with reduced odds of obesity (84).

705

There are a number of important limitations that are central to the interpretation of the data in 706 this study. Genetic correlations from LDSR likely reflect a shared underlying genetic 707 708 architecture, however, this could be mediated by the relationship of the same genetic variants 709 to another variable or variables (7). Despite this limitation, the existence of horizontal 710 pleiotropy between traits is still informative as identifying genes which effect both psychiatric 711 and biochemical traits, and further insight into the mechanisms, would likely refine our 712 understanding of both traits. Moreover, the genetically informed causal inference approaches we implement in this study are subject to limitations regarding the data they are performed 713 714 with and any biases therein, including potential effects of population stratification (85), 715 selection bias (86), and the assumption of acyclicity. The LCV model is also fixed to be 716 bivariate in nature, and thus, the effects of multiple meditators cannot be taken into account. 717 We address this by constructing multivariable MR models such that direct effects are estimated conditioned on likely confounders, however, our selection of confounders is not exhaustive, 718 719 and other unidentified factors may influence our findings. The UKBB sample is also composed 720 of older individuals over the age of 40, and thus, more developmentally sensitive effects on the biochemical traits in question could not be assessed. Genetic variants are also sometimes 721

722	claimed to represent a lifetime effect on a particular variable, although caution is required in
723	this inference given that factors like age may modulate the effect of a variant (87,88). We assert
724	that although GWAS informed causal inference has a number of caveats and limitations it
725	enables an important opportunity to priortise biochemical traits which are putatively clinically
726	relevant in psychiatry and inform future study into these traits.
727	
728	ACKNOWLEDGEMENTS
729	The authors wish to acknowledge Dr Luke O'Connor for his insightful correspondence in
730	relation to some of the LCV data in this study. This work was supported by a National Health
731	and Medical Research Council (NHMRC) grant (1188493). M.J.C. is supported by an
732	NHMRC Senior Research Fellowship (1121474), URL: https://www.nhmrc.gov.au/. The
733	funders had no role in study design, data collection and analysis, decision to publish, or
734	preparation of the paper.
735	
736	DISCLOSURES
737	The authors declare no competing financial interests
738	
739	AUTHOR CONTRIBUTIONS
740	W.R.R. conceived and designed the study with input from M.J.C. W.R.R. performed the
741	primary analyses. M.P.G and D.J.K performed the rho-HESS analyses. J.R.A performed the
742	SNP imputation in the ASRB cohort. M.J.C, V.J.C, and M.J.G contributed the ASRB cohort,
743	as well as to critical interpretation of the results and drafting of the manuscript.
744	
745	
746	

747 **REFERNECES**

- 1. Polderman TJC, Benyamin B, de Leeuw CA, Sullivan PF, van Bochoven A, Visscher PM,
- 749 Posthuma D (2015): Meta-analysis of the heritability of human traits based on fifty
- years of twin studies. *Nat Genet* 47: 702–709.
- 2. Brainstorm Consortium, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et
- 752 *al.* (2018): Analysis of shared heritability in common disorders of the brain. *Science*

753 360. https://doi.org/10.1126/science.aap8757

- 754 3. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address:
- 755 plee0@mgh.harvard.edu, Cross-Disorder Group of the Psychiatric Genomics
- 756 Consortium (2019): Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms

across Eight Psychiatric Disorders. *Cell* 179: 1469-1482.e11.

- 4. Reay WR, Cairns MJ (2020): Pairwise common variant meta-analyses of schizophrenia
 with other psychiatric disorders reveals shared and distinct gene and gene-set
 associations. *Transl Psychiatry* 10: 134.
- 5. Gamazon ER, Zwinderman AH, Cox NJ, Denys D, Derks EM (2019): Multi-tissue
- transcriptome analyses identify genetic mechanisms underlying neuropsychiatric
 traits. *Nat Genet* 51: 933–940.
- 6. Byrne EM, Zhu Z, Qi T, Skene NG, Bryois J, Pardinas AF, et al. (2020): Conditional
- GWAS analysis to identify disorder-specific SNPs for psychiatric disorders. *Mol Psychiatry*. https://doi.org/10.1038/s41380-020-0705-9
- 767 7. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, *et al.* (2015): An
 768 atlas of genetic correlations across human diseases and traits. *Nat Genet* 47: 1236–
 769 1241.
- 8. Burgess S, Butterworth A, Thompson SG (2013): Mendelian randomization analysis with
 multiple genetic variants using summarized data. *Genet Epidemiol* 37: 658–665.

- 9. O'Connor LJ, Price AL (2018): Distinguishing genetic correlation from causation across
 52 diseases and complex traits. *Nat Genet* 50: 1728–1734.
- 10. Chan MK, Guest PC, Levin Y, Umrania Y, Schwarz E, Bahn S, Rahmoune H (2011):
- 775 Converging evidence of blood-based biomarkers for schizophrenia. *International*
- *Review of Neurobiology*, vol. 101. Elsevier, pp 95–144.
- 11. Lai C-Y, Scarr E, Udawela M, Everall I, Chen WJ, Dean B (2016): Biomarkers in
- schizophrenia: A focus on blood based diagnostics and theranostics. *World J Psychiatry* 6: 102–117.
- 12. Carvalho AF, Solmi M, Sanches M, Machado MO, Stubbs B, Ajnakina O, et al. (2020):
- 781 Evidence-based umbrella review of 162 peripheral biomarkers for major mental
 782 disorders. *Transl Psychiatry* 10: 152.
- 13. Meduna LJ (1942): BIOCHEMICAL DISTURBANCES IN MENTAL DISORDERS: I.
- 784 ANTI-INSULIN EFFECT OF BLOOD IN CASES OF SCHIZOPHRENIA. *Arch*785 *NeurPsych* 47: 38.
- 14. Kim JH, Kim JY, Lee J, Jeong GH, Lee E, Lee S, *et al.* (2020): Environmental risk
- factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. *The Lancet Psychiatry* 7: 955–970.
- 15. Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ (2015): Cytokine
 aberrations in autism spectrum disorder: a systematic review and meta-analysis. *Mol*
- 791 *Psychiatry* 20: 440–446.
- 792 16. Brown NC, Andreazza AC, Young LT (2014): An updated meta-analysis of oxidative
 793 stress markers in bipolar disorder. *Psychiatry Res* 218: 61–68.
- 17. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. (2019):
- 795 Discovery of the first genome-wide significant risk loci for attention
- 796 deficit/hyperactivity disorder. *Nat Genet* 51: 63–75.

- 18. Watson HJ, Yilmaz Z, Thornton LM, Hübel C, Coleman JRI, Gaspar HA, et al. (2019):
- 798 Genome-wide association study identifies eight risk loci and implicates metabo-
- psychiatric origins for anorexia nervosa. *Nat Genet* 51: 1207–1214.
- 800 19. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. (2019):
- 801 Identification of common genetic risk variants for autism spectrum disorder. *Nat*802 *Genet* 51: 431–444.
- 20. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. (2019):

804 Genome-wide association study identifies 30 loci associated with bipolar disorder.
805 *Nat Genet* 51: 793–803.

- 21. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al.
- 807 (2018): Genome-wide association analyses identify 44 risk variants and refine the
 808 genetic architecture of major depression. *Nat Genet* 50: 668–681.
- 809 22. Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen C-Y, Choi KW, et al.

810 (2019): International meta-analysis of PTSD genome-wide association studies

811 identifies sex- and ancestry-specific genetic risk loci. *Nat Commun* 10: 4558.

- 812 23. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S,
- 813 Walters JT, O'Donovan MC (2020): *Mapping Genomic Loci Prioritises Genes and*
- 814 *Implicates Synaptic Biology in Schizophrenia*. Genetic and Genomic Medicine.
- 815 https://doi.org/10.1101/2020.09.12.20192922

816 24. Yu D, Sul JH, Tsetsos F, Nawaz MS, Huang AY, Zelaya I, et al. (2019): Interrogating the

- 817 Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through
 818 Genome-Wide Association Studies. *Am J Psychiatry* 176: 217–227.
- 819 25. Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA, et al. (2018):
- 820 Genome-wide association meta-analysis in 269,867 individuals identifies new genetic
- and functional links to intelligence. *Nat Genet* 50: 912–919.

822	26. Scrucca L, Fop M, Murphy TB, Raftery AE (2016): mclust 5: Clustering, Classification
823	and Density Estimation Using Gaussian Finite Mixture Models. R J 8: 289–317.
824	27. Hallmayer JF, Kalaydjieva L, Badcock J, Dragovic M, Howell S, Michie PT, et al.
825	(2005): Genetic evidence for a distinct subtype of schizophrenia characterized by
826	pervasive cognitive deficit. Am J Hum Genet 77: 468-476.
827	28. Green MJ, Cairns MJ, Wu J, Dragovic M, Jablensky A, Tooney PA, et al. (2013):
828	Genome-wide supported variant MIR137 and severe negative symptoms predict
829	membership of an impaired cognitive subtype of schizophrenia. Mol Psychiatry 18:
830	774–780.
831	29. Loughland C, Draganic D, McCabe K, Richards J, Nasir A, Allen J, et al. (2010):
832	Australian Schizophrenia Research Bank: a database of comprehensive clinical,
833	endophenotypic and genetic data for aetiological studies of schizophrenia. Aust NZJ
834	<i>Psychiatry</i> 44: 1029–1035.
835	30. Reay WR, Atkins JR, Quidé Y, Carr VJ, Green MJ, Cairns MJ (2020): Polygenic
836	disruption of retinoid signalling in schizophrenia and a severe cognitive deficit
837	subtype. Mol Psychiatry 25: 719–731.
838	31. Reay WR, Atkins JR, Carr VJ, Green MJ, Cairns MJ (2020): Pharmacological enrichment
839	of polygenic risk for precision medicine in complex disorders. Sci Rep 10: 879.
840	32. Lee SH, Goddard ME, Wray NR, Visscher PM (2012): A better coefficient of
841	determination for genetic profile analysis. Genet Epidemiol 36: 214–224.
842	33. Reay WR, Shair SE, Geaghan MP, Riveros C, Holiday EG, McEvoy MA, et al. (2020):
843	Genetically Informed Precision Drug Repurposing for Lung Function and
844	Implications for Respiratory Infection. Respiratory Medicine.
845	https://doi.org/10.1101/2020.06.25.20139816

846	34. Ligthart S.	Vaez A.	Võsa U	Statho	poulou MG.	de Vi	ries PS.	Prins BP	, et al. ((2018)):
		,		,		,			,	(3

- 847 Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation
- 848 and Highlight Pathways that Link Inflammation and Complex Disorders. *Am J Hum*
- 849 *Genet* 103: 691–706.
- 850 35. Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), Lagou V,
- 851 Mägi R, Hottenga J-J, Grallert H, Perry JRB, *et al.* (2021): Sex-dimorphic genetic
- effects and novel loci for fasting glucose and insulin variability. *Nat Commun* 12: 24.
- 36. Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, et al. (2019): Target
- genes, variants, tissues and transcriptional pathways influencing human serum urate
 levels. *Nat Genet* 51: 1459–1474.
- 856 37. Wheeler E, Leong A, Liu C-T, Hivert M-F, Strawbridge RJ, Podmore C, et al. (2017):
- 857 Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk
 858 and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta859 analysis. *PLoS Med* 14: e1002383.
- 38. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG (2017): Sensitivity Analyses for
 Robust Causal Inference from Mendelian Randomization Analyses with Multiple
 Genetic Variants. *Epidemiology* 28: 30–42.
- 39. Bowden J, Davey Smith G, Haycock PC, Burgess S (2016): Consistent Estimation in
 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
 Estimator. *Genet Epidemiol* 40: 304–314.
- 40. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM (2020): A robust and efficient
- 867 method for Mendelian randomization with hundreds of genetic variants. *Nat Commun*868 11: 376.

869	41. Hartwig FP, Davey Smith G, Bowden J (2017): Robust inference in summary data
870	Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol
871	46: 1985–1998.
872	42. Bowden J, Davey Smith G, Burgess S (2015): Mendelian randomization with invalid
873	instruments: effect estimation and bias detection through Egger regression. Int J
874	<i>Epidemiol</i> 44: 512–525.
875	43. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR
876	(2016): Assessing the suitability of summary data for two-sample Mendelian
877	randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J
878	<i>Epidemiol</i> 45: 1961–1974.
879	44. Rees JMB, Wood AM, Dudbridge F, Burgess S (2019): Robust methods in Mendelian
880	randomization via penalization of heterogeneous causal estimates. PLoS One 14:
881	e0222362.
882	45. Bowden J, Hemani G, Davey Smith G (2018): Invited Commentary: Detecting Individual
883	and Global Horizontal Pleiotropy in Mendelian Randomization-A Job for the Humble
884	Heterogeneity Statistic? Am J Epidemiol 187: 2681–2685.
885	46. Verbanck M, Chen C-Y, Neale B, Do R (2018): Detection of widespread horizontal
886	pleiotropy in causal relationships inferred from Mendelian randomization between
887	complex traits and diseases. Nat Genet 50: 693-698.
888	47. Burgess S, Labrecque JA (2018): Mendelian randomization with a binary exposure
889	variable: interpretation and presentation of causal estimates. Eur J Epidemiol 33:
890	947–952.
891	48. Adams DM, Reay WR, Geaghan MP, Cairns MJ (2020): Investigation of glycaemic traits
892	in psychiatric disorders using Mendelian randomisation revealed a causal relationship

893	with anorexia nervosa. Neuropsychopharmacology. https://doi.org/10.1038/s41386-
894	020-00847-w
895	49. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. (2015): Genetic
896	studies of body mass index yield new insights for obesity biology. Nature 518: 197-
897	206.
898	50. Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Frånberg M, Sennblad B, et al.
899	(2017): Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular
900	disease. PLoS Genet 13: e1006706.
901	51. Sanderson E, Davey Smith G, Windmeijer F, Bowden J (2019): An examination of
902	multivariable Mendelian randomization in the single-sample and two-sample
903	summary data settings. International Journal of Epidemiology 48: 713–727.
904	52. Sanderson E, Spiller W, Bowden J (2020): Testing and Correcting for Weak and
905	Pleiotropic Instruments in Two-Sample Multivariable Mendelian Randomisation.
906	Genetics. https://doi.org/10.1101/2020.04.02.021980
907	53. Grant AJ, Burgess S (2020): Pleiotropy robust methods for multivariable Mendelian
908	randomization. arXiv:200811997 [stat]. Retrieved March 1, 2021, from
909	http://arxiv.org/abs/2008.11997
910	54. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. (2018): The
911	MR-Base platform supports systematic causal inference across the human phenome.
912	<i>eLife</i> 7: e34408.
913	55. Yavorska OO, Burgess S (2017): MendelianRandomization: an R package for performing
914	Mendelian randomization analyses using summarized data. Int J Epidemiol 46: 1734-
915	1739.

916 56. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani A
--

- 917 Plagnol V (2014): Bayesian test for colocalisation between pairs of genetic
- 918 association studies using summary statistics. *PLoS Genet* 10: e1004383.
- 919 57. Shi H, Mancuso N, Spendlove S, Pasaniuc B (2017): Local Genetic Correlation Gives
- 920 Insights into the Shared Genetic Architecture of Complex Traits. *Am J Hum Genet*
- **921** 101: 737–751.
- 922 58. Berisa T, Pickrell JK (2016): Approximately independent linkage disequilibrium blocks
 923 in human populations. *Bioinformatics* 32: 283–285.
- 924 59. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J (2019): g:Profiler:
- 925 a web server for functional enrichment analysis and conversions of gene lists (2019
 926 update). *Nucleic Acids Research* 47: W191–W198.
- 927 60. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, *et al.* (2018):
 928 Genomic atlas of the human plasma proteome. *Nature* 558: 73–79.
- 929 61. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. (2019):
- 930 STRING v11: protein-protein association networks with increased coverage,
- 931 supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids*
- **932** *Res* 47: D607–D613.
- 933 62. Solmi F, Bulik CM, De Stavola BL, Dalman C, Khandaker GM, Lewis G (2020):
- 934 Longitudinal associations between circulating interleukin-6 and C-reactive protein in
- 935 childhood, and eating disorders and disordered eating in adolescence. *Brain*,
- 936 *Behavior, and Immunity* 89: 491–500.
- 937 63. Chang JP-C, Mondelli V, Satyanarayanan SK, Chiang Y-J, Chen H-T, Su K-P, Pariante
- 938 CM (2020): Cortisol, inflammatory biomarkers and neurotrophins in children and
- adolescents with attention deficit hyperactivity disorder (ADHD) in Taiwan. Brain,
- 940 *Behavior, and Immunity* 88: 105–113.

941	64. Fond G, Lançor	C, Auquier P, Boye	er L (2018): C-Reac	tive Protein as a Peripheral
-----	--------------------	--------------------	---------------------	------------------------------

- 942 Biomarker in Schizophrenia. An Updated Systematic Review. *Front Psychiatry* 9:
 943 392.
- 944 65. Hartwig FP, Borges MC, Horta BL, Bowden J, Davey Smith G (2017): Inflammatory
- 945 Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study.
 946 *JAMA Psychiatry* 74: 1226.
- 947 66. Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, et al. (2016):
- 948 Investigating the Causal Relationship of C-Reactive Protein with 32 Complex
- 949 Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian
 950 Randomization Study. *PLoS Med* 13: e1001976.
- 951 67. Ligthart S (2019): Commentary: CRP and schizophrenia: cause, consequence or
 952 confounding? *Int J Epidemiol* 48: 1514–1515.
- 68. Reay WR, Cairns MJ (2020): The role of the retinoids in schizophrenia: genomic and
 clinical perspectives. *Mol Psychiatry* 25: 706–718.
- 955 69. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. (2016): The Allelic
- 956 Landscape of Human Blood Cell Trait Variation and Links to Common Complex
 957 Disease. *Cell* 167: 1415-1429.e19.
- 958 70. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, *et al.* (2020): The
 959 Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* 182: 1214960 1231.e11.
- 961 71. Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, Rumsey J, et al. (1990):
- 962 Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset. N
 963 *Engl J Med* 323: 1361–1366.
- 964 72. Lindblad F, Eickhoff M, Forslund AH, Isaksson J, Gustafsson J (2015): Fasting blood
 965 glucose and HbA1c in children with ADHD. *Psychiatry Res* 226: 515–516.

966 /3. Bevdoun MA. Canas J-A. Dore GA. Bevdoun HA. Rostant OS. Fanelli-Kuc

967 *et al.* (2016): Serum Uric Acid and Its Association with Longitudinal Cognitive

968 Change Among Urban Adults. *J Alzheimers Dis* 52: 1415–1430.

- 969 74. Singh JA, Cleveland JD (2018): Comparative effectiveness of allopurinol versus
- 970 febuxostat for preventing incident dementia in older adults: a propensity-matched971 analysis. *Arthritis Res Ther* 20: 167.
- 972 75. Sproston NR, Ashworth JJ (2018): Role of C-Reactive Protein at Sites of Inflammation
 973 and Infection. *Front Immunol* 9: 754.
- 974 76. Slaats J, ten Oever J, van de Veerdonk FL, Netea MG (2016): IL-1β/IL-6/CRP and IL-
- 975 18/ferritin: Distinct Inflammatory Programs in Infections ((J. B. Bliska, editor)). *PLoS*976 *Pathog* 12: e1005973.
- 977 77. Del Giudice M, Gangestad SW (2018): Rethinking IL-6 and CRP: Why they are more
 978 than inflammatory biomarkers, and why it matters. *Brain, Behavior, and Immunity* 70:
 979 61–75.
- 980 78. Jacomb I, Stanton C, Vasudevan R, Powell H, O'Donnell M, Lenroot R, et al. (2018): C-
- 981 Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical
 982 Thickness in Schizophrenia and Healthy Controls. *Front Immunol* 9: 2230.

983

984 sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex.
985 *Neuropharmacology* 108: 403–414.

79. Li Y-C, Yang S-S, Gao W-J (2016): Disruption of Akt signaling decreases dopamine

- 986 80. Solmi M, Veronese N, Favaro A, Santonastaso P, Manzato E, Sergi G, Correll CU
- 987 (2015): Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-
- 988 sectional and longitudinal studies. *Psychoneuroendocrinology* 51: 237–252.

- 989 81. Patsalos O, Dalton B, Himmerich H (2020): Effects of IL-6 Signaling Pathway Inhibition
- 990 on Weight and BMI: A Systematic Review and Meta-Analysis. *Int J Mol Sci* 21.
- 991 https://doi.org/10.3390/ijms21176290
- 992 82. Tiosano S, Yavne Y, Watad A, Langevitz P, Lidar M, Feld J, et al. (2020): The impact of
- 993 tocilizumab on anxiety and depression in patients with rheumatoid arthritis. *Eur J*
- 994 *Clin Invest* 50. https://doi.org/10.1111/eci.13268
- 83. Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, *et al.* (2021): The IL-6
 antagonist tocilizumab is associated with worse depression and related symptoms in
- 997 the medically ill. *Transl Psychiatry* 11: 58.
- 998 84. Abramovitch A, Anholt GE, Cooperman A, van Balkom AJLM, Giltay EJ, Penninx BW,
- 999 van Oppen P (2019): Body mass index in obsessive-compulsive disorder. J Affect
 1000 Disord 245: 145–151.
- 1001 85. Koellinger PD, de Vlaming R (2019): Mendelian randomization: the challenge of
 1002 unobserved environmental confounds. *International Journal of Epidemiology* 48:
- 1003 665–671.
- 1004 86. Gkatzionis A, Burgess S (2019): Contextualizing selection bias in Mendelian
- 1005 randomization: how bad is it likely to be? *International Journal of Epidemiology* 48:1006 691–701.
- 1007 87. Davies NM, Holmes MV, Davey Smith G (2018): Reading Mendelian randomisation
 1008 studies: a guide, glossary, and checklist for clinicians. *BMJ* k601.
- 1009 88. Labrecque JA, Swanson SA (2019): Interpretation and Potential Biases of Mendelian
- 1010 Randomization Estimates With Time-Varying Exposures. *American Journal of*1011 *Epidemiology* 188: 231–238.
- 1012
- 1013

Supplementary Figure 1



Supplementary Figure 1. Analysis of an LCV model violation in the HbA1c to PTSD model. As outlined in the supplementary text, we demonstrated that the two mixed fourth moments (cokurtosis) estimates for HbA1c to PTSD were opposite in sign, with an outlier jackknifed estimate of which suggests discordant SNP effects relative to the genome-wide signal. Conversely, the CRP to AN and CRP to MDD had consistent signs of and relative to each other and the genetic correlation. In both CRP models, , which implies GCP > 0.

Supplementary Figure 2





30

20

-log 10(p)

log 10(p)

Supplementary Figure 2. The effect of different prior probabilities for the hypothesis that the SZ and CRP share a same causal variant. Each of these plots represent the colocalisation results for the five regions outlined in supplementary table 24, in order from region 1 to 5, left to right, top to bottom. We plot the effects of varying the default prior



probability for the shared causal variant above or below its default of $1 \ge 10^{-5}$.

Supplementary Figure 3



Supplementary Figure 3. Local genetic covariance and correlation between schizophrenia and CRP as estimated by ρ -HESS. The first two panels are estimates of local genetic correlation and covariance for each approximately independent LD block throughout the genome. Coloured bars represent significant estimates. The remaining two panels are local estimates SNP heritability in those same regions for CRP and SZ, respectively.